Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study

Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study

Background: Early treatment with remdesivir (RMD) or monoclonal antibodies (mAbs) could be a valuable tool in patients at risk of severe COVID-19 with unsatisfactory responses to vaccination. We aim to assess the safety and clinical outcomes of these treatments among immunocompromised subjects. Meth...

Full description

Bibliographic Details
Main Authors: Simona Biscarini, Simone Villa, Camilla Genovese, Mara Tomasello, Anna Tonizzo, Marco Fava, Nathalie Iannotti, Matteo Bolis, Bianca Mariani, Antonia Grazia Valzano, Letizia Corinna Morlacchi, Francesca Donato, Giuseppe Castellano, Ramona Cassin, Maria Carrabba, Antonio Muscatello, Andrea Gori, Alessandra Bandera, Andrea Lombardi
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
monoclonal antibodies
sotrovimab
remdesivir
early treatments
COVID-19
Online Access:https://www.mdpi.com/2227-9059/10/8/2002

Internet

https://www.mdpi.com/2227-9059/10/8/2002

Similar Items